Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cisplatin
/ administration & dosage
Cohort Studies
Creatinine
/ blood
Deoxycytidine
/ administration & dosage
Female
Fluid Therapy
/ methods
Humans
Hyponatremia
/ blood
Kidney Diseases
/ blood
Male
Middle Aged
Retrospective Studies
Sodium
/ blood
Urinary Bladder Neoplasms
/ blood
Urologic Neoplasms
/ blood
Gemcitabine
Gemcitabine cisplatin
Short hydration method
Urothelial carcinoma
Journal
Oncology
ISSN: 1423-0232
Titre abrégé: Oncology
Pays: Switzerland
ID NLM: 0135054
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
02
2020
accepted:
04
03
2020
pubmed:
3
6
2020
medline:
17
9
2020
entrez:
3
6
2020
Statut:
ppublish
Résumé
Conventional first-line chemotherapy for patients with metastatic urothelial carcinoma (UC) is gemcitabine and cisplatin (GC). However, cisplatin can cause renal failure, necessitating abundant fluid replacement and hospitalization during treatment. Recent evidence exists for short hydration methods in cisplatin-based chemotherapy. This study aims to analyze the efficacy of newly established modified short hydration GC (m-shGC) therapy in patients with UC. From May 2017 to March 2019, 48 patients with UC who received m-shGC therapy were treated with 1,000 mg/m2 gemcitabine on days 1, 8, and 15, and 70 mg/m2 cisplatin and 2,000 mL fluid replacement on day 1, in each 28-day cycle. We retrospectively evaluated renal function, serum electrolyte abnormalities, and adverse events (AEs) following treatment, and retrospectively compared patients under m-shGC therapy with those under conventional GC (c-GC) therapy from 2015 to 2017. In addition, from April 2019 to August 2019 in a prospective analysis, 15 patients were newly enrolled, and AE profiles and physical activity during m-shGC therapy were quantified using a wearable tracker. In a retrospective analysis of 101 patients (53 c-GC and 48 m-shGC), patient characteristics were not statistically significant between the two groups. Myelosuppression, including predominant neutropenia and decreased platelets, fatigue, nausea, and constipation were the main common AEs. However, renal function and serum sodium levels in the m-shGC group remained unchanged. Grade 3-4 AEs were not more severe in the m-shGC compared with the c-GC group. Furthermore, in a prospective analysis using a wearable tracker, the amount of walking by patients on day 1 significantly declined. However, immediate recovery occurred reflecting the short hydration. Our m-shGC therapy has an acceptable AE profile compared with conventional therapy, with UC patients showing good physical activity.
Identifiants
pubmed: 32485713
pii: 000506992
doi: 10.1159/000506992
pmc: PMC7592929
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Sodium
9NEZ333N27
Creatinine
AYI8EX34EU
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-620Informations de copyright
© 2020 The Author(s) Published by S. Karger AG, Basel.
Références
Best Pract Res Clin Endocrinol Metab. 2012 Mar;26 Suppl 1:S1-6
pubmed: 22469246
Tumori. 2007 Mar-Apr;93(2):138-44
pubmed: 17557559
J Pharm Health Care Sci. 2016 Mar 05;2:6
pubmed: 26949541
Clin Genitourin Cancer. 2016 Jun;14(3):e257-63
pubmed: 26462439
Eur J Cancer. 2006 Jan;42(1):50-4
pubmed: 16330205
Jpn J Clin Oncol. 1998 Aug;28(8):497-501
pubmed: 9769784
J Oncol. 2014;2014:767652
pubmed: 25328521
J Clin Oncol. 2000 May;18(9):1921-7
pubmed: 10784633
Cancer J. 2005 Nov-Dec;11(6):461-73
pubmed: 16393480
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
JMIR Mhealth Uhealth. 2019 Jan 29;7(1):e11898
pubmed: 30694198
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
Bull Cancer. 2012 Apr 1;99(4):E43-8
pubmed: 22450449
BMC Cardiovasc Disord. 2017 Dec 29;17(1):303
pubmed: 29284402
Jpn J Clin Oncol. 2016 Apr;46(4):370-7
pubmed: 26755829
Sensors (Basel). 2017 Jan 22;17(1):
pubmed: 28117736
Contemp Clin Trials. 2015 Nov;45(Pt B):371-376
pubmed: 26427563
Jpn J Clin Oncol. 2016 Oct;46(10):958-963
pubmed: 27432452
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cancer J. 2005 Nov-Dec;11(6):449-60
pubmed: 16393479
Int J Clin Oncol. 2020 Apr;25(4):541-551
pubmed: 31811602
J Clin Oncol. 1997 Jul;15(7):2564-9
pubmed: 9215826
Jpn J Clin Oncol. 2013 Nov;43(11):1105-9
pubmed: 24006505
Nephrol Dial Transplant. 2014 Apr;29 Suppl 2:i1-i39
pubmed: 24569496
Int J Clin Oncol. 2016 Feb;21(1):81-7
pubmed: 26093520
Int J Hematol Oncol Stem Cell Res. 2017 Oct 1;11(4):262-267
pubmed: 29340120